Presentation is loading. Please wait.

Presentation is loading. Please wait.

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations  Christina Baik,

Published byJoão Gabriel Dreer Modified over 5 years ago

Similar presentations

Presentation on theme: "P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations  Christina Baik,"— Presentation transcript:

1 P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations  Christina Baik, Bernardo Goulart, Katherine Nguyen, Sylvia Lee, Keith Eaton, Laura Chow, Cristina Rodriguez, Rafael Santana-Davila, Rebecca Wood, Renato Martins  Journal of Thoracic Oncology  Volume 12, Issue 1, (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, DOI: (10. 1016/j. jtho. 2016. 11
Copyright © Terms and Conditions

Download ppt "P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations  Christina Baik,"

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC  Hatim Husain,

P3.02b-001 Phase 1 Dose Escalation of PF (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC  Hatim Husain,
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.
Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Robert Pirker, MD, Felix J. F. Herth, MD, PhD, FCCP, Keith M

Robert Pirker, MD, Felix J. F. Herth, MD, PhD, FCCP, Keith M
P1.08-020 The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.
OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy  Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,

OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy  Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,
P2.03b-003 Mutation Profile & Histology According to ERS/ATC/IASCL Associated with IPFS to WBI in BM Patients with Recent Adenocarcinoma Lung Cancer 

P2.03b-003 Mutation Profile & Histology According to ERS/ATC/IASCL Associated with IPFS to WBI in BM Patients with Recent Adenocarcinoma Lung Cancer 
P2.04-054 Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.

P Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.
Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)

Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,

Similar presentations

Ads by Google